- NRx Pharmaceuticals (NRXP, Financial) and HOPE Therapeutics to participate in an H.C. Wainwright fireside chat on April 22, 2025.
- The event will feature Dr. Jonathan Javitt, CEO of NRXP and HOPE Therapeutics, in conversation with HCW Senior Biotech Analyst, Vernon Bernardino.
- The webcast will be accessible via the company's investor relations website.
NRx Pharmaceuticals, Inc. (NRXP), a clinical-stage biopharmaceutical company, will join forces with its wholly-owned subsidiary, HOPE Therapeutics, for a significant event. They are set to participate in an H.C. Wainwright fireside chat scheduled for Tuesday, April 22, 2025, at 10:00 AM EDT.
The discussion will include Dr. Jonathan Javitt, the Founder, Chairman, and CEO of NRx Pharmaceuticals, who also serves as the Co-CEO of HOPE Therapeutics. Vernon Bernardino, HCW's Senior Biotech Analyst, will lead the chat, providing insights into the company's developments.
Investors interested in the event can tune in via a webcast available on the company's investor relations website at ir.nrxpharma.com/events. Additionally, they may contact their HC Wainwright representative for registration details.
NRx Pharmaceuticals is notably advancing in the biotechnology sector, specifically focusing on its NMDA platform for the treatment of central nervous system disorders. The company is currently developing NRX-101, a breakthrough therapy for treatment-resistant bipolar depression, chronic pain, and PTSD. The firm aims to file an NDA for accelerated approval of NRX-101 in managing bipolar depression and suicidality.
